Hap Trading, LLC Biomarin Pharmaceutical Inc Put Options Transaction History

Hap Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 12, 2024	SELL	$69.02 - $93.84 $986,986 - $1.34 Million	-14,300 Reduced 31.09%	31,700 $625 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $3.42 Million - $4.24 Million	46,000 New	46,000 $38.6 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $918,808 - $1.06 Million	10,600 New	10,600 $918,000
Q2 2021 Aug 11, 2021	SELL	$75.51 - $84.79 $1.16 Million - $1.31 Million	-15,400 Reduced 54.23%	13,000 $101,000
Q1 2021 May 14, 2021	BUY	$74.73 - $90.69 $313,866 - $380,898	4,200 Added 17.36%	28,400 $173,000
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $159,742 - $198,440	-2,200 Reduced 8.33%	24,200 $77,000
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $14.4 Million - $26.2 Million	-200,100 Reduced 88.34%	26,400 $164,000
Q3 2018 Nov 09, 2018	SELL	$93.92 - $105.72 $112,704 - $126,864	-1,200 Reduced 0.53%	226,500 $280,000
Q2 2018 Aug 13, 2018	BUY	$76.01 - $99.03 $17.3 Million - $22.5 Million	227,700 New	227,700 $690,000
Q1 2018 May 11, 2018	SELL	$77.67 - $92.63 $4.51 Million - $5.38 Million	-58,100 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$80.76 - $95.13 $4.69 Million - $5.53 Million	58,100	58,100 $63,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.